New Zealand markets closed
  • NZX 50

    11,065.15
    -37.69 (-0.34%)
     
  • NZD/USD

    0.6536
    +0.0053 (+0.81%)
     
  • NZD/EUR

    0.6086
    +0.0050 (+0.83%)
     
  • ALL ORDS

    7,413.10
    +73.80 (+1.01%)
     
  • ASX 200

    7,182.70
    +76.80 (+1.08%)
     
  • OIL

    114.87
    +0.78 (+0.68%)
     
  • GOLD

    1,857.10
    +3.20 (+0.17%)
     
  • NASDAQ

    12,620.55
    +343.77 (+2.80%)
     
  • FTSE

    7,585.46
    +20.54 (+0.27%)
     
  • Dow Jones

    33,043.53
    +406.34 (+1.25%)
     
  • DAX

    14,462.19
    +230.90 (+1.62%)
     
  • Hang Seng

    20,697.36
    +581.16 (+2.89%)
     
  • NIKKEI 225

    26,781.68
    +176.84 (+0.66%)
     
  • NZD/JPY

    83.0180
    +0.7010 (+0.85%)
     

Why Heron Therapeutics Shares Rose Nearly 15% This Week

·2-min read
Why Heron Therapeutics Shares Rose Nearly 15% This Week

The company announced on Thursday that its drug Zynrelef (bupivacaine and meloxicam) has been given Food and Drug Administration supplemental New Drug Application approval for more uses. The drug, the first FDA-approved dual-acting anesthetic, had already been approved in May for post-surgical pain relief after the removal of bunions, open inguinal hernia operations, or total knee replacement in adults. It has shown to be more effective than just bupivacaine alone, the current standard of care for post-surgical pain, and it gives surgeons a non-opioid solution for post-surgical pain, reducing the possibility of addiction.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting